MktsMarkets

Regeneron Pharmaceuticals, Inc.
NASDAQ: REGNKey statistics
REGN News
Stories mentioning REGN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 3,605,400 | 3,884,300 | 3,754,300 | 3,675,600 | 3,028,700 | 3,789,200 | 3,720,700 | 3,547,100 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 1,543,500 | 1,626,100 | 1,475,000 | 1,421,700 | 1,327,400 | 1,412,100 | 1,271,500 | 1,200,000 |
| Sales General & Admin | 647,700 | 775,000 | 657,800 | 634,200 | 633,000 | 792,200 | 714,400 | 758,800 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 642,900 | 879,900 | 1,026,800 | 1,079,500 | 591,700 | 990,200 | 1,179,500 | 1,069,600 |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 201,200 | 176,000 | 755,800 | 442,800 | 322,000 | (21,600) | 327,300 | 573,300 |
| Pretax Income | 831,200 | 1,043,700 | 1,763,300 | 1,518,700 | 905,000 | 958,100 | 1,493,000 | 1,628,100 |
| Tax Provision | 104,000 | 199,100 | 303,300 | 127,100 | 96,300 | 40,400 | 152,400 | 195,800 |
| Net Income (Loss) | 727,200 | 844,600 | 1,460,000 | 1,391,600 | 808,700 | 917,700 | 1,340,600 | 1,432,300 |
| Earnings Per Share (Basic) | 6.99 | 8.07 | 14.09 | 13.24 | 7.58 | 8.51 | 12.40 | 13.25 |
| Earnings Per Share (Diluted) | 6.75 | 7.78 | 13.62 | 12.81 | 7.27 | 7.97 | 11.54 | 12.41 |
| Weighted Average Shares Outstanding (Basic) | 104,000 | 104,600 | 103,600 | 105,100 | 106,700 | 107,900 | 108,100 | 108,100 |
| Weighted Average Shares Outstanding (Diluted) | 107,700 | 108,600 | 107,200 | 108,600 | 111,200 | 115,100 | 116,200 | 115,400 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About REGN
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a stock listed on the Nasdaq Stock Market under the ticker symbol REGN. It last traded at $904.35 (Nov 6, 2026, 4:00 PM ET), up 0.2% on the day. That gives Regeneron Pharmaceuticals a market capitalisation of $93.4B and a price-to-earnings ratio of 19.4.
Over the past 52 weeks REGN has traded between $591.52 and $991.73.
Revenue for the quarter ended Mar 31, 2026 was $3.6B; net income $727.2M. Revenue was up 19.0% from $3.0B in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $3.6B | $727.2M | 20.2% |
| Dec 31, 2025 | $3.9B | $844.6M | 21.7% |
| Sep 30, 2025 | $3.8B | $1.5B | 38.9% |
| Jun 30, 2025 | $3.7B | $1.4B | 37.9% |
From Regeneron Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…